Cargando…

Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model

Although several agents have been identified to provide therapeutic benefits in Huntington disease (HD), the number of conventionally used treatments remains limited and only symptomatic. Thus, it is plausible that the need to identify new therapeutic targets for the development of alternative and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Pardo, Alba, Pepe, Giuseppe, Castaldo, Salvatore, Marracino, Federico, Capocci, Luca, Amico, Enrico, Madonna, Michele, Giova, Susy, Jeong, Se Kyoo, Park, Bu-Mahn, Park, Byeong Deog, Maglione, Vittorio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491579/ https://www.ncbi.nlm.nih.gov/pubmed/31068790 http://dx.doi.org/10.3389/fnmol.2019.00100

Ejemplares similares

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
por: Burtscher, Johannes, et al.
Publicado: (2021)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2018)

Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage
por: Pepe, Giuseppe, et al.
Publicado: (2021)

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Blood–Brain Barrier Integrity Is Perturbed in a Mecp2-Null Mouse Model of Rett Syndrome
por: Pepe, Giuseppe, et al.
Publicado: (2023)

Treatment with the Glycosphingolipid Modulator THI Rescues Myelin Integrity in the Striatum of R6/2 HD Mice
por: Pepe, Giuseppe, et al.
Publicado: (2023)

Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget
por: Hatoum, Diana, et al.
Publicado: (2017)

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models
por: Di Pardo, Alba, et al.
Publicado: (2016)

The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum–microglia crosstalk preventing disease progression in a mouse model of Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2020)

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington’s disease transgenic R6/2 (160 CAG) mice
por: Di Pardo, A., et al.
Publicado: (2017)

An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma
por: Pan, Jian, et al.
Publicado: (2011)

Sphingosine Kinase-1 (SphK-1) Regulates Mycobacterium smegmatis Infection in Macrophages
por: Prakash, Hridayesh, et al.
Publicado: (2010)

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells
por: Lu, Pei-Hua, et al.
Publicado: (2017)

A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease
por: Burtscher, Johannes, et al.
Publicado: (2021)

Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
por: Bu, Yanhong, et al.
Publicado: (2021)

Bioactive compounds from the seeds of Amomum tsaoko Crevost et Lemaire, a Chinese spice as inhibitors of sphingosine kinases, SPHK1/2
por: Lee, Seulah, et al.
Publicado: (2019)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis
por: Wang, Shushu, et al.
Publicado: (2018)

Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo
por: Xun, Cai, et al.
Publicado: (2015)

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease
por: Di Pardo, Alba, et al.
Publicado: (2013)

Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1)
por: Lu, Zhanping, et al.
Publicado: (2015)

Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner
por: Burtscher, Johannes, et al.
Publicado: (2020)

Effects of Inhibition of Serine Palmitoyltransferase (SPT) and Sphingosine Kinase 1 (SphK1) on Palmitate Induced Insulin Resistance in L6 Myotubes
por: Mikłosz, Agnieszka, et al.
Publicado: (2013)

Sphk1 and Sphk2 Differentially Regulate Erythropoietin Synthesis in Mouse Renal Interstitial Fibroblast-like Cells
por: Hafizi, Redona, et al.
Publicado: (2022)

Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells
por: Bazzazi, Hojjat, et al.
Publicado: (2017)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Polysialic Acid Sustains the Hypoxia-Induced Migration and Undifferentiated State of Human Glioblastoma Cells
por: Rosa, Paolo, et al.
Publicado: (2022)

SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells
por: Liu, Hong, et al.
Publicado: (2017)

Krüppel-like factor 12 regulates aging ovarian granulosa cell apoptosis by repressing SPHK1 transcription and sphingosine-1-phosphate (S1P) production
por: Zhang, Chun-Xue, et al.
Publicado: (2023)

Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk
por: Schiefler, Carlotta, et al.
Publicado: (2014)

Pathological roles of the VEGF/SphK pathway in Niemann–Pick type C neurons
por: Lee, Hyun, et al.
Publicado: (2014)

Transforming Growth Factor β1 (TGF-β1) Appears to Promote Coronary Artery Disease by Upregulating Sphingosine Kinase 1 (SPHK1) and Further Upregulating Its Downstream TIMP-1
por: Wang, Shoudong, et al.
Publicado: (2018)

Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis
por: Di Meo, Francesco, et al.
Publicado: (2019)

SphK2 over-expression promotes osteosarcoma cell growth
por: Xu, Dawei, et al.
Publicado: (2017)

Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors
por: Geng, Shuangshuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3srkugoiti8quaclopit04ejp0